-
2023
-
FDA’s approval of Friedreich’s ataxia drug is a game changer for treatment of rare diseases
-
Gene Therapy Consortium to Launch Rare Diseases Pilot
-
ForCast Orthopedics Gets QIDP Nod for Investigational Antibiotic
-
Confo hands baton to Lilly for non-opioid pain med development
-
Jazz Pharmaceuticals Loses REMS Patent Appeal
-
US spent nearly $32B in public funds on mRNA vaccine development, study finds
-
Lilly slashes insulin price 70%, patient cost cap now $35
-
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib
-
Future of generative AI in pharma
-
FDA will review Eisai and Biogen’s Alzheimer’s treatment Leqembi with decision on full approval expected in early July